-
1
-
-
0028304413
-
Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines
-
Mamenta EL, Poma EE, Kaufmann WK, et al. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1994; 54: 3500-5.
-
(1994)
Cancer Res
, vol.54
, pp. 3500-3505
-
-
Mamenta, E.L.1
Poma, E.E.2
Kaufmann, W.K.3
-
2
-
-
0029904811
-
The role of DNA mismatch repair in platinum drug resistance
-
Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881-6.
-
(1996)
Cancer Res
, vol.56
, pp. 4881-4886
-
-
Fink, D.1
Nebel, S.2
Aebi, S.3
-
5
-
-
0025020085
-
Phase I study of oxaliplatin in patients with advanced cancer
-
Extra JM, Espié M, Calvo F, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299-303.
-
(1990)
Cancer Chemother Pharmacol
, vol.25
, pp. 299-303
-
-
Extra, J.M.1
Espié, M.2
Calvo, F.3
Mignot, L.4
Marty, M.5
-
6
-
-
0001704607
-
Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: Preliminary activity/toxicity report
-
Becouarn Y, Ychou M, Ducreux M, et al. Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity/toxicity report. Proc Am Soc Clin Oncol 1997; 16: 229a.
-
(1997)
Proc Am Soc Clin Oncol
, vol.16
-
-
Becouarn, Y.1
Ychou, M.2
Ducreux, M.3
-
7
-
-
0012797224
-
Two consecutive phase two studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous fluoropyrimidines
-
Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase two studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous fluoropyrimidines. Ann Oncol 1996; 7: 95-8.
-
(1996)
Ann Oncol
, vol.7
, pp. 95-98
-
-
Machover, D.1
Diaz-Rubio, E.2
De Gramont, A.3
-
8
-
-
0001385726
-
Oxaliplatin (L-OHP) and cisplatin (CDDP) in combination with 5-FU, specific thymidylate synthase (TS) inhibitors (AG337, ZD1694) and topoisomerase I (Topo-I) inhibitors (SN38, CPT-11), in human colonic, ovarian and breast cancers
-
Raymond E, Djelloul C, Buquet-Fagot F, et al. Oxaliplatin (L-OHP) and cisplatin (CDDP) in combination with 5-FU, specific thymidylate synthase (TS) inhibitors (AG337, ZD1694) and topoisomerase I (Topo-I) inhibitors (SN38, CPT-11), in human colonic, ovarian and breast cancers (meeting abstract). Proc Am Ass Cancer Res 1996; 291: 37.
-
(1996)
Proc Am Ass Cancer Res
, vol.291
, pp. 37
-
-
Raymond, E.1
Djelloul, C.2
Buquet-Fagot, F.3
-
9
-
-
0028036652
-
Chronomodulated versus fixed-infusion-rate delivery ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial
-
Lévi F, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed-infusion-rate delivery ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608-17.
-
(1994)
J Natl Cancer Inst
, vol.86
, pp. 1608-1617
-
-
Lévi, F.1
Zidani, R.2
Vannetzel, J.M.3
-
10
-
-
0030888321
-
Oxaliplatin with high dose leucovorin and 5-fluorouracil 48-hour infusion in pretreated metastatic colorectal cancer
-
de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high dose leucovorin and 5-fluorouracil 48-hour infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33: 214-9.
-
(1997)
Eur J Cancer
, vol.33
, pp. 214-219
-
-
De Gramont, A.1
Vignoud, J.2
Tournigand, C.3
-
11
-
-
0025979845
-
A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma
-
Ardalan B, Chua L, Hudes GR, et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991; 9: 625-30.
-
(1991)
J Clin Oncol
, vol.9
, pp. 625-630
-
-
Ardalan, B.1
Chua, L.2
Hudes, G.R.3
-
12
-
-
0025338285
-
Phase-I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate
-
Caussanel JP, Lévi F, Brienza S, et al. Phase-I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82: 1046-50.
-
(1990)
J Natl Cancer Inst
, vol.82
, pp. 1046-1050
-
-
Caussanel, J.P.1
Lévi, F.2
Brienza, S.3
-
13
-
-
0027461840
-
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
-
Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 752-5.
-
(1993)
Br Med J
, vol.306
, pp. 752-755
-
-
Scheithauer, W.1
Rosen, H.2
Kornek, G.V.3
-
14
-
-
0026721532
-
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer evidence in terms of response rate
-
Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
-
(1992)
J Clin Oncol
, vol.10
, pp. 896-903
-
-
-
15
-
-
0031019918
-
Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer
-
de Gramont A, Bosset JF, Milan C, et al. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. J Clin Oncol 1997; 15: 805-15.
-
(1997)
J Clin Oncol
, vol.15
, pp. 805-815
-
-
De Gramont, A.1
Bosset, J.F.2
Milan, C.3
-
16
-
-
0031015454
-
Fluorouracil in colorectal cancer: A tale of two drugs: Implications for biochemical modulation
-
Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer: a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997; 15: 368-81.
-
(1997)
J Clin Oncol
, vol.15
, pp. 368-381
-
-
Sobrero, A.F.1
Aschele, C.2
Bertino, J.R.3
-
17
-
-
0028213430
-
Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma
-
Weh HJ, Wilke J, Dierlamm J, et al. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994; 5: 233-7.
-
(1994)
Ann Oncol
, vol.5
, pp. 233-237
-
-
Weh, H.J.1
Wilke, J.2
Dierlamm, J.3
-
18
-
-
0343255312
-
Irinotecan (CPT-11) multicenter phase II study in colorectal cancer patients with documented progressive disease on prior 5FU: Preliminary results
-
Vancutsem E, Cunningham D, Ten Bokkel Huinink W, et al. Irinotecan (CPT-11) multicenter phase II study in colorectal cancer patients with documented progressive disease on prior 5FU: preliminary results. Proc Am Soc Clin Oncol 1996; 15: 230.
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
, pp. 230
-
-
Vancutsem, E.1
Cunningham, D.2
Ten Bokkel Huinink, W.3
-
19
-
-
0023708345
-
The definition of the 'No Change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast
-
Howell A, Mackintosh J, Jones M, Redford J, Wagstaff J, Sellwood RA. The definition of the 'No Change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Clin Oncol 1996; 24: 1557-72.
-
(1996)
Eur J Clin Oncol
, vol.24
, pp. 1557-1572
-
-
Howell, A.1
Mackintosh, J.2
Jones, M.3
Redford, J.4
Wagstaff, J.5
Sellwood, R.A.6
-
20
-
-
0028060451
-
The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer
-
Graf W, Pahlman L, Bergstrom R, Glimelius B. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 1994; 70: 559-63.
-
(1994)
Br J Cancer
, vol.70
, pp. 559-563
-
-
Graf, W.1
Pahlman, L.2
Bergstrom, R.3
Glimelius, B.4
|